Valve-in-valve TAVR (ViV-TAVR) of a failed surgical valve was associated with comparable—and perhaps even better—clinical outcomes when compared to TAVR performed in native valves, according to a registry study published in the Journal of the American College of Cardiology.

The FDA has approved the third generation of the MitraClip, which treats mitral regurgitation without open-heart surgery, device manufacturer Abbott announced July 12.

Scientists are beginning to explore whether infusing heart tissue with mitochondria can restore function to oxygen-deprived cells after a heart attack. The technique has potential in both pediatric and adult patients, according to an article in The New York Times.

Nearly all transcatheter heart valves (THVs) leave debris following aortic valve replacement, reinforcing the potential for embolic protection devices to reduce the burden of silent brain infarctions and future strokes.

Transcatheter valve-in-valve replacement for degenerated mitral bioprostheses was associated with similar 30-day and one-year mortality rates as redo surgical mitral valve replacement (SMVR) in a retrospective study, despite the former being performed in older, sicker patients.

Mutations in the CHD4 gene are known contributors to congenital heart defects. Biologists at the University of North Carolina School of Medicine believe they are beginning to understand why.

An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

Despite being performed in an older population with more cardiovascular comorbidities, transcatheter aortic valve replacement (TAVR) demonstrated similarly low rates of postoperative stroke and mortality compared with surgical aortic valve replacement (SAVR) in a study of patients with previous strokes.